Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?

Price, Louise S.

doi:10.1136/ejhpharm-2016-001155

Cited by 9 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interventions outlined in Table 1 provide practical recommendations which can be implemented to meet the needs of patients during the dynamics of a pandemic. 5–50…”

Section: Altering System Cancer Regimensmentioning

confidence: 99%

Clinical strategies for optimizing infusion center care through a pandemic

Hanna

Segal

Barlow

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

The national pandemic resulting from the novel coronavirus, COVID-19, has made the delivery of care for patients with cancer a challenge. There are competing risks of mortality from cancer versus serious complications and higher risk of death from COVID-19 in immunocompromised hosts. Furthermore, compounding these concerns is the inadequate supply of personal protective equipment, decreased hospital capacity, and paucity of effective treatments or vaccines to date for COVID-19. Guidance measures and recommendations have been published by national organizations aiming to facilitate the delivery of care in a safe and effective manner, many of which, are permanently adoptable interventions. Given the critical importance to continue chemotherapy, there remains additional interventions to further enhance patient safety while conserving healthcare resources such as adjustments in medication administration, reduction in laboratory or drug monitoring, and home delivery of specialty infusions. In this manuscript, we outline how to implement these actionable interventions of chemotherapy and supportive care delivery to further enhance the current precautionary measures while maintaining safe and effective patient care. Coupled with current published standards, these strategies can help alleviate the numerous challenges associated with this pandemic.

show abstract

“…Interventions outlined in Table 1 provide practical recommendations which can be implemented to meet the needs of patients during the dynamics of a pandemic. 5–50…”

Section: Altering System Cancer Regimensmentioning

confidence: 99%

Clinical strategies for optimizing infusion center care through a pandemic

Hanna

Segal

Barlow

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“… 8 A combined therapy of trastuzumab and pertuzumab plus docetaxel is a first-line treatment in the metastatic setting. 7 , 9 …”

Section: Introductionmentioning

confidence: 99%

“…Trastuzumab, a recombinant human monoclonal IgG1 antibody that targets the epidermal growth factor 2 (HER2) protein, is used for the treatment of breast cancer HER2-positive. 7 As a single agent, it is a potent adjuvant against breast cancer; however, a synergic effect can be observed when this chemotherapy is associated with other drugs. 8 A combined therapy of trastuzumab and pertuzumab plus docetaxel is a first-line treatment in the metastatic setting.…”

Section: Introductionmentioning

confidence: 99%

“…8 A combined therapy of trastuzumab and pertuzumab plus docetaxel is a first-line treatment in the metastatic setting. 7,9 It is known, however, that docetaxel is a cytotoxic agent that often presents several acute and long-term secondary effects. Generally, several acute secondary effects such as fever, dyspnea, hypoxia, urticaria, and cardiorespiratory arrest can occur within minutes or hours after drug administration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report

Sarría

Arencibia

D’Afonseca

2020

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

We report the case of a 42-year-old woman who was diagnosed with breast cancer that recurred 3 years later, with supraclavicular lymphadenopathy and dermal involvement. The main drug used in the therapy was trastuzumab; however, the association of this drug with docetaxel was not able to decrease or cease the effect of the inflammatory BCA component with erythema and thickening of the skin as well as the supraclavicular lymphadenopathy previously diagnosed. Thus, a combined therapy was required. The patient was started on 6 cycles (1 per month) of trastuzumab subcutaneous 600 mg, pertuzumab intravenous 840 mg (as an attack dose, later on 420 mg), and xeloda oral 1000 mg. As a result, the patient showed a significant improvement in erythema and thickening of the skin in the neck and the right part of her trunk, besides decrease in supraclavicular lymphadenopathy. After 6 cycles, her skin was almost restored. Intravenous trastuzumab can be an effective single agent; however, its association with other chemotherapies—such as pertuzumab—can present a synergic effect, which can increase the survival expectations of metastatic HER2+ patients. Additionally, as reported in the literature, the use of xeloda plays a key role in restoring the skin health of patients with breast cancer presenting with skin metastasis. Our findings suggest that trastuzumab, pertuzumab, and xeloda combined therapy, following the schedule and posology handled in this study, can be a good treatment for recurrent HER2+ breast cancer with signs of supraclavicular lymphadenopathy and severe inflammatory BCA component with erythema and thickening of the skin.

show abstract

“…Trastuzumab is known to induce HSRs in 16% of patients, and these take the form of anaphylaxis in 2% of cases [9]. When a patient presents with an HSR to biologics, doctors tend to administer an alternative treatment [4], thus compromising the patient's prognosis by avoiding the optimal first-line treatment [4].…”

mentioning

confidence: 99%